Ishares Biotechnology Etf Fundamentals
| IBB Etf | USD 139.91 1.95 1.41% |
iShares Biotechnology ETF fundamentals help investors to digest information that contributes to IShares Biotechnology's financial success or failures. It also enables traders to predict the movement of IShares Etf. The fundamental analysis module provides a way to measure IShares Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IShares Biotechnology etf.
IShares |
iShares Biotechnology ETF ETF Price To Sales Analysis
IShares Biotechnology's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current IShares Biotechnology Price To Sales | 4.94 X |
Most of IShares Biotechnology's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, iShares Biotechnology ETF is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
IShares Biotechnology Price To Sales Component Assessment
Based on the latest financial disclosure, iShares Biotechnology ETF has a Price To Sales of 4.94 times. This is much higher than that of the iShares family and 86.77% higher than that of the Health category. The price to sales for all United States etfs is notably lower than that of the firm.
iShares Biotechnology ETF Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining IShares Biotechnology's current stock value. Our valuation model uses many indicators to compare IShares Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IShares Biotechnology competition to find correlations between indicators driving IShares Biotechnology's intrinsic value. More Info.iShares Biotechnology ETF is considered the top ETF in price to earning as compared to similar ETFs. It also is considered the top ETF in price to book as compared to similar ETFs fabricating about 1.07 of Price To Book per Price To Earning. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the IShares Biotechnology's earnings, one of the primary drivers of an investment's value.IShares Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IShares Biotechnology's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of IShares Biotechnology could also be used in its relative valuation, which is a method of valuing IShares Biotechnology by comparing valuation metrics of similar companies.IShares Biotechnology is currently under evaluation in price to sales as compared to similar ETFs.
Fund Asset Allocation for IShares Biotechnology
The fund invests 99.93% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides IShares Biotechnology's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
IShares Fundamentals
| Price To Earning | 3.16 X | |||
| Price To Book | 3.39 X | |||
| Price To Sales | 4.94 X | |||
| Earnings Per Share | (11.38) X | |||
| Beta | 0.85 | |||
| Market Capitalization | 9.22 B | |||
| Total Asset | 7.41 B | |||
| One Year Return | 16.50 % | |||
| Three Year Return | (3.20) % | |||
| Five Year Return | 3.90 % | |||
| Ten Year Return | 3.60 % | |||
| Net Asset | 7.41 B | |||
| Last Dividend Paid | 0.39 | |||
| Equity Positions Weight | 99.93 % |
About IShares Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze iShares Biotechnology ETF's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IShares Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of iShares Biotechnology ETF based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.The fund generally will invest at least 80 percent of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Nasdaq Biotechnology is traded on NASDAQ Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iShares Biotechnology ETF offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Biotechnology Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Biotechnology Etf:Check out IShares Biotechnology Piotroski F Score and IShares Biotechnology Altman Z Score analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.